Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Gross Profit (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Gross Profit for 16 consecutive years, with $164.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit rose 2.42% to $164.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $722.7 million, a 3.68% increase, with the full-year FY2024 number at $693.3 million, down 6.86% from a year prior.
  • Gross Profit was $164.9 million for Q3 2025 at Usana Health Sciences, down from $185.7 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $294.5 million in Q1 2022 to a low of $50.9 million in Q4 2022.
  • A 5-year average of $195.1 million and a median of $186.7 million in 2022 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: tumbled 82.71% in 2022, then skyrocketed 251.03% in 2023.
  • Usana Health Sciences' Gross Profit stood at $223.6 million in 2021, then tumbled by 77.23% to $50.9 million in 2022, then surged by 251.03% to $178.8 million in 2023, then dropped by 2.07% to $175.1 million in 2024, then fell by 5.83% to $164.9 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Gross Profit are $164.9 million (Q3 2025), $185.7 million (Q2 2025), and $197.1 million (Q1 2025).